These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 33553708)

  • 1. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
    Patel S; Saxena B; Mehta P
    Heliyon; 2021 Feb; 7(2):e06158. PubMed ID: 33553708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
    Farooqi F; Dhawan N; Morgan R; Dinh J; Nedd K; Yatzkan G
    Trop Med Infect Dis; 2020 Jul; 5(3):. PubMed ID: 32635353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.
    Shibabaw T
    J Inflamm Res; 2020; 13():673-680. PubMed ID: 33116747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model.
    Gu T; Zhao S; Jin G; Song M; Zhi Y; Zhao R; Ma F; Zheng Y; Wang K; Liu H; Xin M; Han W; Li X; Dong CD; Liu K; Dong Z
    Front Immunol; 2020; 11():621441. PubMed ID: 33584719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on the effects of
    Aucoin M; Cardozo V; McLaren MD; Garber A; Remy D; Baker J; Gratton A; Kala MA; Monteiro S; Warder C; Perciballi A; Cooley K
    Metabol Open; 2021 Sep; 11():100115. PubMed ID: 34341776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs based regulation of cytokine regulating immune expressed genes and their transcription factors in COVID-19.
    Khokhar M; Tomo S; Purohit P
    Meta Gene; 2022 Feb; 31():100990. PubMed ID: 34722158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection.
    Qudus MS; Tian M; Sirajuddin S; Liu S; Afaq U; Wali M; Liu J; Pan P; Luo Z; Zhang Q; Yang G; Wan P; Li Y; Wu J
    J Med Virol; 2023 Apr; 95(4):e28751. PubMed ID: 37185833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations.
    Mehta Y; Dixit SB; Zirpe KG; Ansari AS
    Indian J Crit Care Med; 2020 Jun; 24(6):429-434. PubMed ID: 32863636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
    J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting the storm: could novel anti-TNFα and anti-IL-6
    Kovalchuk A; Wang B; Li D; Rodriguez-Juarez R; Ilnytskyy S; Kovalchuk I; Kovalchuk O
    Aging (Albany NY); 2021 Jan; 13(2):1571-1590. PubMed ID: 33465050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaco-Immunomodulatory Therapy in COVID-19.
    Rizk JG; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Forthal DN
    Drugs; 2020 Sep; 80(13):1267-1292. PubMed ID: 32696108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
    Cure E; Kucuk A; Cure MC
    Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine/Chemokine Expression Is Closely Associated Disease Severity of Human Adenovirus Infections in Immunocompetent Adults and Predicts Disease Progression.
    Li J; Wei J; Xu Z; Jiang C; Li M; Chen J; Li Y; Yang M; Gu Y; Wang F; Shu Y; Yang Y; Sun L; Liu Y
    Front Immunol; 2021; 12():691879. PubMed ID: 34163488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).
    Norooznezhad AH; Mansouri K
    Microvasc Res; 2021 Sep; 137():104188. PubMed ID: 34022205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Targeting of IL-1-Signaling and IL-6-Trans-Signaling Preserves Human Pulmonary Endothelial Barrier Function During a Cytokine Storm-Brief Report.
    Colás-Algora N; Muñoz-Pinillos P; Cacho-Navas C; Avendaño-Ortiz J; de Rivas G; Barroso S; López-Collazo E; Millán J
    Arterioscler Thromb Vasc Biol; 2023 Nov; 43(11):2213-2222. PubMed ID: 37732482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.